Deletion of TIM-3 on CD4+ and CD8+ T cells reduced tumour burden and loss of TIM-3 in DC cells enhanced antigen-specific anti-tumour immunity, expanded stem-like CD8+ cells and activation inflammasome pathways48. The gene discussed is HAVCR2; the disease is neoplasm.